Impact of medical therapy on transurethral resection of the prostate: Two decades of change

BJU International

Volumn 108, Issue 1, 2011, Pages 89-93

  Izard, Jason ^a   Nickel, J Curtis ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b KINGSTON GENERAL HOSPITAL   (Canada)

Author keywords

5 alpha reductase therapy; alpha blocker; benign prostatic hyperplasia; lower urinary tract symptoms; medical therapy; transurethral resection of the prostate

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; STEROID 5ALPHA REDUCTASE INHIBITOR;

ACUTE DISEASE; ADULT; ARTICLE; BODY WEIGHT; CATHETER REMOVAL; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; HEALTH STATUS; HOSPITAL DISCHARGE; HUMAN; HYDRONEPHROSIS; LENGTH OF STAY; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PREOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RISK ASSESSMENT; SURGICAL RISK; TRANSURETHRAL RESECTION; TREATMENT FAILURE; TREATMENT INDICATION; URETHRAL CATHETERIZATION; URINARY TRACT INFECTION; URINE RETENTION;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-ANTAGONISTS; AGED; DRUG THERAPY, COMBINATION; EPIDEMIOLOGIC METHODS; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSTATIC HYPERPLASIA; PROSTATISM; TRANSURETHRAL RESECTION OF PROSTATE; TREATMENT OUTCOME; URINARY CATHETERIZATION;

EID: 79959295338     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09737.x     Document Type: Article

References (9)

1. Girman CJ, Jacobsen SJ, Tsukamoto T, et al,. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998; 51: 428-36 (Pubitemid 28136681)
2. Flanigan RC, Reda DJ, Wasson JH, Anderson RJ, Abdellatif M, Bruskewitz RC,. 5-Year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol 1998; 160: 12-7 (Pubitemid 29479405)
3. Sarma AV, Jacobson DJ, McGree ME, Roberts RO, Lieber MM, Jacobsen SJ,. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997. J Urol 2005; 173: 2048-53 (Pubitemid 40675240)
4. McConnell JD, Bruskewitz R, Walsh P, et al,. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338: 557-63 (Pubitemid 28114643)
5. Nickel JC, Sander S, Moon TD,. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to Benign Prostatic Hyperplasia. Int J Clin Pract 2008; 62: 1547-59
6. McConnell JD, Roehrborn CG, Bautista OM, et al,. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98 (Pubitemid 37542987)
7. Roehrborn CG, Siami P, Barkin J, et al,. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT Study. Eur Urol 2010; 57: 123-31
8. Borth CS, Beiko DT, Nickel JC,. Impact of medical therapy on transurethral resection of the prostate: a decade of change. Urology 2001; 57: 1082-5 (Pubitemid 32455574)
9. Reich O, Gratzke C, Bachmann A, et al,. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol 2008; 180: 246-9